CYTOKINETICS AND GLAXOSMITHKLINE AMEND COLLABORATION AGREEMENT FOR SB-743921 Maturation of Cytokinetics' Capabilities Enables Increased Responsibility for Clinical Development under Augmented Development Program for KSP InhibitorsCollaboration Agreement |
|
|
You are currently viewing: This Collaboration Agreement involves
Burns McClellan, Inc | Cytokinetics, Incorporated. RealDealDocs™ contains millions of easily searchable legal documents and clauses from top law firms. Search for free - click here. |
|
|
|
Search Collaboration Agreement by:
Exhibit 99.1
|
|
|
|
|
Contacts: |
|
|
|
|
|
|
|
Cytokinetics,
Incorporated |
|
Burns McClellan, Inc. |
|
Robert I. Blum |
|
Clay Kramer (investors) |
|
EVP, Corporate
Development and Commercial Operations & CBO |
|
Justin Jackson (media) |
|
(650) 624-3000 |
|
(212) 213-0006 |
CYTOKINETICS AND GLAXOSMITHKLINE AMEND COLLABORATION
AGREEMENT FOR SB-743921
Maturation of Cytokinetics’ Capabilities Enables
Increased Responsibility
for Clinical Development under Augmented Development Program for KSP Inhibitors
South San Francisco,
CA, September 27, 2005 — Cytokinetics,
Incorporated (Nasdaq: CYTK) announced the amendment of the company’s
strategic alliance with GlaxoSmithKline (GSK), which will provide Cytokinetics
an expanded role in clinical research and development for SB-743921, a novel,
small molecule inhibitor of kinesin spindle protein (KSP). This drug candidate
is being developed under an alliance focused on novel small molecule
therapeutics targeting human mitotic kinesins for applications in the treatment
of cancer and other diseases.
Under the terms of the
amendment, Cytokinetics will lead and fund development activities to explore
the potential application of SB-743921 for the treatment of non-Hodgkin’s
lymphoma, Hodgkin’s lymphoma and multiple myeloma, subject to the option
for GSK to resume responsibility for development and commercialization
activities for SB-743921 for these indications during a defined period.
Cytokinetics’ development activities will be conducted in parallel with
GSK’s conduct of development activities for SB-743921 in other
indications and for ispinesib (SB-715992). Ispinesib is the first
drug candidate to emerge from the strategic alliance and is currently the
subject of a broad clinical trials program pursuant to the alliance.
The amendment provides for acceleration of the
